Drug development
and diagnostics
Choose the relevant keywords from the list to search for research groups on those specific areas. As the search is cumulative, choose only a few keywords for a general search and more keywords for more refined search. To see all research groups, click the selection underneath the list.
Turku Metabolomics Centre
Main categories: Diagnostics, Drug discovery
The Turku Metabolomics Centre (TMC) was established in the Fall of 2017, and currently comprises four analytical laboratories on the University of Turku and Åbo Academy campuses, with the primary focus on biomedical and clinical applications. TMC covers a broad range of analytical methods, useful for discovery studies, hypothesis-driven targeted studies as well as clinical applications in Good Laboratory Practice (GLP) setting. The methods include:
1. Targeted quantitative analyses by mass spectrometry (MS) of specific groups of metabolites, e.g. bile acids, endocannabinoids, amino acids, eicosanoids.
2. Global profiling of molecular lipids (lipidomics) and polar metabolites.
3. Diagnostic, drug metabolism and pharmacokinetic applications in Good Laboratory Practice (GLP) setting.
4. Tissue metabolomics by Nuclear Magnetic Resonance (NMR).
5. How dietary intake affects blood metabolism.
TMC infrastructure currently includes 7 MS instruments (2 x UHPLC-QTRAP/QqQ-MS, 2 x UHPLC-QqQ-MS, 1 x GC-QqQ-MS, 2 x GC-QMS) and 2 NMR instruments (1 x 600 MHz and 1 x 400 MHz). The 400 MHz spectrometer is equipped with a high resolution magic angle spinning probe for the detection of metabolites in tissue and cell samples without the need for extensive sample preparation. The 600MHz instrument is equipped with a cooled sample handling robot with space for 300 samples allowing high throughput liquid NMR studies. Two new MS instruments also being purchased this year.
Drug development and diagnostics is a common research profiling area of the University of Turku and Åbo Akademi University funded by the Academy of Finland. This website is a part of this joint initiative bringing together all information that is related to drug discovery and development or diagnostics from both universities.
